Meldonium
Also known as: Mildronate, MET-88, THP
Metabolic Modulator | Endurance & Cardioprotection
Overview
Meldonium (marketed as Mildronate) is a cardioprotective and anti-ischemic drug developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. It is approved and widely prescribed in Latvia, Lithuania, Russia, and several other post-Soviet states for the treatment of coronary artery disease, heart failure, and cerebrovascular conditions. Meldonium has never been approved by the FDA or EMA, and it remains unavailable through conventional pharmaceutical channels in the United States and most of Western Europe. The drug gained worldwide notoriety in March 2016 when tennis star Maria Sharapova announced she had tested positive for meldonium after the World Anti-Doping Agency (WADA) added it to the Prohibited List effective January 1, 2016. Her positive test was far from isolated -- WADA reported that meldonium was the most common substance detected in doping control samples in early 2016, with hundreds of athletes across multiple sports testing positive, predominantly from Eastern European and Central Asian countries. This widespread use reflected meldonium's longstanding popularity among athletes in those regions, where it was both legally available by prescription and culturally accepted as a general-purpose cardioprotective and performance-enhancing agent. In the performance enhancement community, meldonium has attracted particular interest among anabolic steroid users seeking cardiac protection during cycles, given the well-documented cardiotoxic effects of supraphysiological androgen use including left ventricular hypertrophy, impaired diastolic function, and accelerated atherosclerosis.
Key benefits
- Cardioprotective effects through metabolic optimization under ischemic conditions
- Shifts cardiac energy metabolism from fatty acid oxidation to more oxygen-efficient glucose oxidation
- Reduces accumulation of toxic fatty acid intermediates (long-chain acylcarnitines) in heart tissue
- Promotes nitric oxide synthesis and endothelial function via GBB accumulation
- May improve exercise capacity and reduce recovery time through enhanced glucose utilization
- Used as adjunctive cardiac protection during anabolic steroid cycles to mitigate androgen-induced cardiotoxicity
- Well-established safety profile in Eastern European clinical use spanning over 30 years
Mechanism of action
Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time. Since carnitine is essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, reduced carnitine levels impair fatty acid beta-oxidation. This forces cells -- particularly cardiomyocytes and skeletal muscle cells -- to shift their metabolic fuel preference from fatty acid oxidation toward glucose oxidation. This metabolic shift is the cornerstone of meldonium's cardioprotective mechanism. Under ischemic conditions (reduced blood flow), fatty acid oxidation becomes metabolically inefficient and even harmful: incomplete fatty acid oxidation generates toxic intermediates (long-chain acylcarnitines and acyl-CoA species) that damage cell membranes and impair mitochondrial function. Glucose oxidation, by contrast, requires less oxygen per molecule of ATP produced and does not generate these toxic intermediates. By forcing the heart to rely more on glucose, meldonium effectively optimizes energy production under oxygen-limited conditions and reduces the accumulation of cardiotoxic lipid metabolites. Additionally, the accumulation of GBB that results from BBOX inhibition has been shown to stimulate nitric oxide (NO) production via an ester-mediated mechanism, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance. Meldonium also upregulates the expression of glucose transporter proteins (GLUT-1 and GLUT-4) and activates components of the Akt-dependent cardioprotective signaling pathway, further enhancing myocardial resistance to ischemic injury.
Molecular data
- Type
- Hydrazinium derivative (C6H14N2O2)
- Half-life
- ~4-6 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Cardiovascular & Metabolic
Investigational / Off-Label
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 500 mg/day | Once daily or split into two doses (250 mg twice daily) | — |
| — | 500-1000 mg/day | Once daily or split into two doses | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Mild gastrointestinal discomfort (nausea, dyspepsia, or stomach upset -- typically transient and dose-dependent)
- Occasional heartburn or acid reflux, especially at higher doses or when taken on an empty stomach
Rare side effects
- Allergic skin reactions (rash, pruritus -- infrequently reported)
- Mild tachycardia or palpitations
- Headache or dizziness
- Agitation or sleep disturbance (rare, more common at higher doses)
Contraindications
- Known hypersensitivity to meldonium or any excipients
- Pregnancy or breastfeeding (insufficient safety data)
- Individuals under 18 years of age
- Severe hepatic or renal impairment (limited pharmacokinetic data in these populations)
- Increased intracranial pressure (listed as a contraindication in some regional prescribing information)
Monitoring
- Blood pressure and heart rate: baseline and periodically throughout the cycle
- Lipid panel: baseline and at 4-6 weeks, as the metabolic shift may affect lipid profiles
- Basic metabolic panel including renal function: baseline and mid-cycle
- Consider echocardiogram at baseline if using for steroid-related cardioprotection, to establish cardiac structure and function benchmarks
References
Primary literature and clinical-trial data informing this entry.